For: | Duan F, Bai YH, Cui L, Li XH, Yan JY, Wang MQ. Simultaneous transarterial chemoembolization and radiofrequency ablation for large hepatocellular carcinoma. World J Gastrointest Oncol 2020; 12(1): 92-100 [PMID: 31966917 DOI: 10.4251/wjgo.v12.i1.92] |
---|---|
URL: | https://www.wjgnet.com/1948-5204/full/v12/i1/92.htm |
Number | Citing Articles |
1 |
Ronald S. Arellano. What’s New in Percutaneous Ablative Strategies for Hepatocellular Carcinoma and Colorectal Hepatic Metastases? 2020 Update. Current Oncology Reports 2020; 22(10) doi: 10.1007/s11912-020-00967-y
|
2 |
Liang Zhang, Kuishuai Xu, Xuehui Zhang, Linqian Li, Jing Chong, Ning Yu. A meta-analysis and trial sequential analysis of high intensity focused ultrasound ablation combined with transhepatic arterial chemotherapy and embolization for hepatoma. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.1025177
|
3 |
Yun-Long Qin, Shuai Wang, Fei Chen, Hong-Xiu Liu, Kui-Tao Yue, Xi-Zhen Wang, Hou-Fa Ning, Peng Dong, Xiang-Rong Yu, Guang-Zhi Wang. Prediction of outcomes by diffusion kurtosis imaging in patients with large (≥5 cm) hepatocellular carcinoma after liver resection: A retrospective study. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.939358
|
4 |
Chao An, Yan Fu, Wang Li, Mengxuan Zuo, Peihong Wu. Postprogression treatment of lenvatinib plus PD‐1 inhibitor in advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy. Cancer 2023; 129(14): 2235 doi: 10.1002/cncr.34764
|
5 |
Chao An, Wang Yao, Mengxuan Zuo, Wang Li, Qifeng Chen, Peihong Wu. Pseudo-capsulated Hepatocellular Carcinoma: Hepatic Arterial Infusion Chemotherapy Versus Transcatheter Arterial Chemoembolization. Academic Radiology 2024; 31(3): 833 doi: 10.1016/j.acra.2023.06.021
|
6 |
Shen Zhang, Bin-Yan Zhong, Lei Zhang, Wan-Sheng Wang, Cai-Fang Ni. Transarterial chemoembolization failure/refractoriness: A scientific concept or pseudo-proposition. World Journal of Gastrointestinal Surgery 2022; 14(6): 528-537 doi: 10.4240/wjgs.v14.i6.528
|
7 |
Jingyi Dai, Yadi Ding, Qiaomei Zheng, Guixin Zhao, Lingqing Zou, Jun Zhao, Yu Luo, Virasakdi Chongsuvivatwong. Survival Benefits of Transarterial Chemoembolization Plus Ablation Therapy in Patients With Intermediate or Advanced Hepatocellular Carcinoma: A Propensity Score Matching Study. Cancer Management and Research 2025; : 483 doi: 10.2147/CMAR.S511364
|
8 |
Zeno Sparchez, Pompilia Radu, Adrian Bartos, Iuliana Nenu, Rares Craciun, Tudor Mocan, Adelina Horhat, Mihaela Spârchez, Jean-François Dufour. Combined treatments in hepatocellular carcinoma: Time to put them in the guidelines?. World Journal of Gastrointestinal Oncology 2021; 13(12): 1896-1918 doi: 10.4251/wjgo.v13.i12.1896
|
9 |
Lin Zhou, Jing Wang, Shao-cheng Lyu, Li-chao Pan, Xian-jie Shi, Guo-sheng Du, Qiang He. PD-L1+NEUT, Foxp3+Treg, and NLR as New Prognostic Marker with Low Survival Benefits Value in Hepatocellular Carcinoma. Technology in Cancer Research & Treatment 2021; 20 doi: 10.1177/15330338211045820
|
10 |
Chunhui Zhou, Changli Peng, Fei Liu, Juxiong Xiao, Gang Li, Changyong Chen, Liangrong Shi, Haiping Li. Evaluation of the efficacy and safety of CalliSpheres® microsphere-transarterial chemoembolization in large hepatocellular carcinoma. Journal of Cancer Research and Therapeutics 2023; 19(6): 1575 doi: 10.4103/jcrt.jcrt_218_23
|